AbCellera Biologics (ABCL) Operating Leases (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Operating Leases data on file, last reported at $134.3 million in Q1 2026.

• Quarterly Operating Leases rose 112.48% year-over-year to $134.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.3 million (up 112.48% YoY) and the FY2025 annual result came in at $137.4 million, up 126.2% from the prior year.
• Operating Leases slipped to $134.3 million in Q1 2026, from $137.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $137.4 million in Q4 2025 to a low of $32.8 million in Q2 2022.
• A 5-year average of $82.1 million and a median of $75.2 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases jumped 162.58% — and 2024, when it slipped 21.5%.
• Tracing ABCL's Operating Leases over 5 years: stood at $76.7 million in 2022, then gained by 0.92% to $77.4 million in 2023, then fell by 21.5% to $60.7 million in 2024, then jumped by 126.2% to $137.4 million in 2025, then slipped by 2.25% to $134.3 million in 2026.
• The last three Operating Leases figures came in at $134.3 million (Q1 2026), $137.4 million (Q4 2025), and $137.1 million (Q3 2025), per Business Quant data.